Versartis Inc (VSAR) Director Shahzad Malik Sells 483,670 Shares of Stock

Versartis Inc (NASDAQ:VSAR) Director Shahzad Malik sold 483,670 shares of the stock in a transaction that occurred on Friday, March 17th. The stock was sold at an average price of $18.11, for a total transaction of $8,759,263.70. Following the transaction, the director now directly owns 9,200 shares of the company’s stock, valued at approximately $166,612. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shahzad Malik also recently made the following trade(s):

  • On Wednesday, March 15th, Shahzad Malik sold 166,330 shares of Versartis stock. The stock was sold at an average price of $19.09, for a total transaction of $3,175,239.70.

Versartis Inc (NASDAQ:VSAR) traded up 7.59% during midday trading on Monday, reaching $20.55. 322,704 shares of the company’s stock were exchanged. Versartis Inc has a 52 week low of $6.32 and a 52 week high of $24.00. The stock’s 50 day moving average is $17.68 and its 200 day moving average is $14.30. The firm’s market capitalization is $720.20 million.

Versartis (NASDAQ:VSAR) last announced its earnings results on Tuesday, February 21st. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by $0.02. During the same period in the prior year, the business posted ($0.69) EPS. On average, analysts expect that Versartis Inc will post ($2.56) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Your IP Address:

VSAR has been the subject of a number of research analyst reports. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 price objective on shares of Versartis in a research report on Wednesday, February 22nd. Zacks Investment Research raised shares of Versartis from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research report on Friday, January 6th. Credit Suisse Group AG raised shares of Versartis from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $11.00 to $20.00 in a research report on Tuesday, December 20th. SunTrust Banks, Inc. initiated coverage on shares of Versartis in a research report on Thursday, December 1st. They set a “buy” rating and a $25.00 price objective for the company. Finally, Barclays PLC initiated coverage on shares of Versartis in a research report on Thursday, March 9th. They set an “overweight” rating and a $28.00 price objective for the company. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $23.29.

A number of institutional investors have recently made changes to their positions in VSAR. Arrowpoint Asset Management LLC raised its position in Versartis by 32.4% in the fourth quarter. Arrowpoint Asset Management LLC now owns 376,061 shares of the biopharmaceutical company’s stock worth $5,603,000 after buying an additional 92,105 shares in the last quarter. NF Trinity Capital Hong Kong Ltd purchased a new position in Versartis during the third quarter worth $3,000,000. Perceptive Advisors LLC purchased a new position in Versartis during the fourth quarter worth $61,889,000. Aisling Capital LLC raised its position in Versartis by 10.7% in the third quarter. Aisling Capital LLC now owns 2,524,465 shares of the biopharmaceutical company’s stock worth $30,925,000 after buying an additional 244,897 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in Versartis during the third quarter worth $2,450,000. Institutional investors own 70.15% of the company’s stock.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

5 Day Chart for NASDAQ:VSAR

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/versartis-inc-vsar-director-shahzad-malik-sells-483670-shares-of-stock/1709205.html

Receive News & Ratings for Versartis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *